Abstract: Pressurized aerosol composition comprising a liquefied hydrofluorocarbon propellant of formula CxHyFz where x is an integer from 1 to 3, y+z=2x+2, and y and z are both at least 1; from 0.01 to 15% w/w of a particulate medicament dispersed in the liquefied hydrofluorocarbon propellant; and from 0.01 to 10% w/w of a fluorinated surfactant which is soluble in the liquefied hydrofluorocarbon propellant. The pressurized aerosol composition comprises no solvent, other than the liquefied hydrofluorocarbon propellant.

Abstract: This invention relates to aerosol formulations of use for the administration of medicaments by inhalation. More particularly, the invention relates to a pharmaceutical aerosol formulation which comprises particulate salbutamol sulphate having a crystalline form in which the outer layer of the crystals is substantially non-amorphous; and 1,1,1,2-tetrafluoroethane. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as defined is also described.

Abstract: Cosmetic composition for topical application to the skin comprise a cyclodextrin compound and a salicylic acid or salicylic acid derivative, wherein the composition is in the form of a water-in-silicone emulsion having a continuous silicone oil-containing phase and a discontinuous aqueous phase. The compositions herein provide improved anti-acne/anti-inflammatory activity together with reduced skin irritation.

Abstract: Improved aerodynamically light particles for delivery to the pulmonary system, and methods for their preparation and administration are provided. In a preferred embodiment, the aerodynamically light particles are made of a biodegradable material and have a tap density less than 0.4 g/cm3 and a mass mean diameter between 5 &mgr;m and 30 &mgr;m. The particles may be formed of biodegradable mat as biodegradable polymers. For example, the particles may be formed of a functionalized polyester graft copolymer consisting of a linear &agr;-hydroxy-acid polyester backbone having at least one amino acid group incorporated therein and at least one poly(amino acid) side chain extending from an amino acid group in the polyester backbone. In one embodiment, aerodynamically light particles having a large mean diameter, for example greater than 5 &mgr;m, can be used for enhanced delivery of a therapeutic or diagnostic agent to the alveolar region of the lung.

Abstract: A stable ethanolic solution of budesonide is disclosed, which solution is suitable for use in nebulizers, together with a process for making such stable solution.

Abstract: This invention relates to a medicinal aerosol formulation and more particularly, to a medicinal aerosol formulation containing a particulate drug, a propellant and a stabilizing agent selected from an amino acid, an amino acid derivative and a mixture of the foregoing.

Abstract: Compounds of Formula I: wherein: X1, and X2 are each independently either O− or S−; X3 and X4 are each independently either —H or —OH, with the proviso that X3 and X4 are not simultaneously —H; R1 is selected from the group consisting of O, imido, methylene and dihalomethylene; R2 is selected from the group consisting of H, halo, alkyl, substituted alkyl, alkoxyl, nitro and azido; R3 is selected from the group consisting of H, alkyl, acyl, aryl, and arylalkyl; and R4 is selected from the group consisting of —OR′, —SR′, —NR′, and —NR′R″, wherein R′ and R″ are independently selected from the group consisting of H, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, alkoxyl, and aryloxyl, with the proviso that R′ is absent when R4 is double bonded from an oxygen or sulfur atom to the carbon at the 4-position of the pyrimidine ring, are used in methods of hydrating lung mucus secr

Abstract: Provided are pressurized metered dose inhalers containing stable formulations of a &bgr;-agonist drug in suspension or solution. Also provided are aerosol formulations suitable for inhalation therapy containing a &bgr;-agonist drug in suspension or solution.

Abstract: Improved porous particles for drug delivery to the pulmonary system, and methods for their synthesis and administration are provided. In a preferred embodiment, the porous particles are made of a biodegradable material and have a mass density less than 0.4 g/cm3/. The particles may be formed of biodegradable materials such as biodegradable polymers. For example, the particles may be formed of a functionalized polyester graft copolymer consisting of a linear &agr;-hydroxy-acid polyester backbone having at least one amino acid group incorporated therein and at least one poly(amino acid) side chain extending from an amino acid group in the polyester backbone. In one embodiment, porous particles having a relatively large mean diameter, for example greater than 5 &mgr;m, can be used for enhanced delivery of a therapeutic agent to the alveolar region of the lung.

Abstract: A bandage for treating a bacterial infection of skin is disclosed wherein the bandage contains a composition produced by the method of obtaining an effective amount of at least one lytic enzyme genetically coded for by a specific bacteriophage specific for a bacteria infecting the skin, wherein the bacteria to be treated is selected from the group consisting of Staphylococcus, Pseudomonas, Streptococcus, and combinations thereof. This lytic enzyme is specific for and has the ability to digest a cell wall of one of the bacteria and is coded for by the same bacteriophage capable of infecting the bacteria being digested. The enzyme produced is mixed with a topical carrier.

Abstract: A composition for treatment of bacterial infections of the vagina is disclosed which comprises a lytic enzyme composition specific for the infecting bacteria, and a carrier for delivering said lytic enzyme. The lytic enzyme is which is specific for the group B Streptococcus, is genectically coded for by a specific bacteriophage.

Abstract: Drug delivery to the pulmonary system has been achieved by encapsulation of the drug to be delivered in microparticles having a size range between 0.5 and ten microns, preferably in the range of two to five microns, formed of a material releasing drug at a pH of greater than 6.4. In a preferred embodiment, the drug delivery system is based on the formation of diketopiperazine microparticles which are stable at a pH of 6.4 or less and unstable at pH of greater than 6.4, or which are stable at both acidic and basic pH, but which are unstable at pH between about 6.4 and 8. Other types of materials can also be used, including biodegradable natural and synthetic polymers, such as proteins, polymers of mixed amino acids (proteinoids), alginate, and poly(hydroxy acids). In another embodiment, the microparticles have been modified to effect targeting to specific cell types and to effect release only after reaching the targeted cells.

Abstract: An aerosol composition for treating bacterial infections of the respiratory tract by delivering said aerosol to the mouth, throat or nasal passage, wherein the bacteria to be treated is selected from the group consisting of Streptococcus pneumoniae, Haemophilus influenzae, Streptococcus Group A, and combinations thereof, said aerosol comprising an effective amount of at least one lytic enzyme genetically coded by a bacteriophage specific for a specific said bacteria of the respiratory tract, whereby said at least one lytic enzyme has the ability to digest the cell wall of said specific bacteria; and a carrier for delivering said enzyme.

Abstract: Pharmaceutical preparations for producing powder aerosols using propellant gases which use TG 227, and possibly also TG 11, TG 12, TGH 114, propane, butane, pentane or DME.

Abstract: Aerosol formulations substantially free of chlorofluorocarbons, for oral and/or nasal administration are described. The formulations comprise 1,1,1,2 tetrafluoroethane, a medicament, optionally an excipient and optionally a surfactant. Methods of treatment utilizing the formulations also are described.

Abstract: Methods, compounds, and medicinal formulations utilizing biocompatible polymers for delivery of a drug, particularly for solubilizing, stabilizing and/or providing sustained release of drug from topical, implantable, and inhalation systems. Many of the methods, compounds, and medicinal formulations are particularly suitable for oral and/or nasal inhalation and use polymers of the formula —[X—R1—C(O)]— wherein each R1 is an independently selected organic group that links the —X— group to the carbonyl group, and each X is independently oxygen, sulfur, or catenary nitrogen.

Abstract: New advantageous propellent gas mixtures contain two or more components, at least one of which is a partially fluorinated lower alkane, and may be used in pharmaceutical preparations.

Abstract: A device for providing pharmaceutical doses comprising a container, filled with a pharmaceutical composition including a pharmaceutically active agent in a solution of liquified 1,1,1,2-tetrafluoroethane (HFC-134a), or 1,1,1,2,3,3,3 heptafluoropropane (HFC-227) and a carrier. The carrier can be a pharmaceutically acceptable alcohol, polyol, (poly)alkoxy derivative, fatty acid alkyl ester, polyalkylene glycol, or dimethyl sulphoxide. The device includes a valve arranged for delivering aerosol doses of said pharmaceutical composition to the exterior of the container, and at least a portion of the device is formed from a polyester.

Abstract: The present invention relates to a method of exfoliating and moisturizing the skin comprising the steps of topically applying a cosmetic or pharmaceutical composition. The composition comprises an amino sugar, N-acetyl-D-glucosamine and related compounds.

Abstract: A solid elastic and pliable self-supporting wound dressing is formed by mixing dry hydrocolloid polymer powder with water. Preferably the dry polymer powder and water are contained in a sealed package having a temporary or manually-removable barrier so that the dry polymer and waster can be stored separately from each other while in the package. The wound dressing may be prepared by breaking or removing the barrier to allow intermixing of the polymer and water within the package so that a fluid, pourable and spreadable aqueous colloidal dispersion is initially formed within the package and which can be removed from the package and easily poured or spread onto the wound. The initially-formed dispersion then solidifies to form a solid or semi-solid elastic, pliable wound dressing containing water and hydrocolloid. The presence of water in the wound dressing provides desirable moisture during the healing process.